The relevance here is evidential, not procedural: because delivery and stability vary so much, comparing results across products and studies is genuinely difficult, and that heterogeneity is one reason a clean answer to the title question has been so slow to emerge
Breaking down the numbers Your 80mg KLOW vial contains 50mg GHK-Cu, 10mg BPC-157, 10mg TB-500, and 10mg KPV
16 BRTRC Federal Solutions, DoD SBIR Phase III Data from CCR: Data Threshold Information , July 2005
Protocol Used: 0.25 mg BPC-157 subcutaneous injection daily for 6 weeks, administered 2 inches proximal to Achilles insertion point, combined with eccentric heel drops and gradual return to running
I dont think I have it cause I live in Florida but I did go to Georgia and South Carolina before I got sick but had no indication of a tick bite
Oral route data in rodents shows genuine GI-local effects, but systemic bioavailability from capsules is unquantified in humans, meaning dose-response claims for joints and tendons rely on injection-route animal studies